Implantica AG’s RefluxStop Gains Spotlight at DDW Conference

VADUZ, Liechtenstein, May 27, 2025 — Implantica AG, a Swiss-based medical device company specializing in medical implants and instruments, has made significant strides in the U.S. market with its innovative RefluxStop procedure. The company’s pre-launch activities have been met with enthusiasm, as evidenced by the intensive dialogue generated at the Digestive Disease Week (DDW) conference in San Diego, California.

The DDW, recognized as the world’s largest conference in the field of digestive diseases, served as a pivotal platform for Implantica AG to showcase its RefluxStop procedure. With over 13,000 leading surgeons, gastroenterologists, academics, and researchers in attendance, the event highlighted the latest innovations and clinical data in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Implantica AG’s presentations at DDW focused on the unique mechanism of action and the clinical advantages of the RefluxStop procedure. The company’s European real-world clinical evidence has piqued the interest of U.S. surgeons, who are keenly awaiting FDA approval. Dr. med. Zehetner, a prominent figure in the field, shared his real-world knowledge and clinical outcomes, emphasizing the palpable curiosity and interest among the conference attendees.

The successful pre-launch activities in the U.S. underscore Implantica AG’s potential to make a significant impact in the medical implant market. With a market capitalization of 1.63 billion SEK and a primary listing on the Swedish Stock Exchange, the company is well-positioned to capitalize on the growing demand for innovative medical solutions.

As Implantica AG continues to navigate the regulatory landscape in the U.S., the positive reception at DDW bodes well for the future of the RefluxStop procedure. The company’s ability to engage with top experts and leaders in the treatment field highlights its commitment to advancing medical technology and improving patient outcomes.

In summary, Implantica AG’s presence at the DDW conference has not only generated significant interest in the RefluxStop procedure but also reinforced the company’s reputation as a leader in the development and production of medical implants and instruments. With FDA approval on the horizon, Implantica AG is poised to make a substantial impact in the U.S. market, further solidifying its position in the global medical device industry.